KRRO logo

KORRO BIO INC

KRRONASDAQ
πŸ† #3594 by market capEarnings Nov 18US Equity
$13.92β–² $0.60 (+4.50%)
Pre-market Β· at close
πŸ””
Track KRRO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 4.5%
7dβ–² 16.0%
14dβ–² 49.0%
30dβ–² 45.3%
ytdβ–² 73.6%
1yβ–Ό 64.1%
🏦Market Cap
$205M
Small Cap
πŸ“ˆRevenue Growth (YoY)
181.5%
High Growth
πŸ“ŠGross Margin
72.8%
High
πŸ’΅FCF Margin
-2865.9%
Thin
βš–οΈP/S Ratio
82.2x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$13.18 – $14.01
52-Week Range
$5.20 – $42.70
Volume (shares)
18,306
Avg Volume (shares)
β€”
Shares Outstanding
14.7M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
β€”
P/E Ratio
-1.3
P/S Ratio
82.2x
EPS (TTM)
$-6.05
Dividend Yield
0.00%
Dilution (1yr)
+5.3%
KRRO logo

KORRO BIO INC

KRRO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6Mβ–² +181.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
33.0%β–Ό βˆ’67.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$87Mβ–Ό βˆ’5.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$79Mβ–² +1.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.4Mβ–² +5.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$22Mβ–Ό βˆ’$33M YoY
StockOtter Β· stockotter.space

About KORRO BIO INC

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100
Analyst data unavailable.

Latest News & Updates

News unavailable.